Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Por:
Bellido V, Martínez J, Calvo F, Villarroel A, Lecumberri E, Moreno J, Morillas C, Rodrigo S, Izarra A and Lecube A
Publicada:
1 may 2022
Ahead of Print:
1 mar 2022
Resumen:
Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is associated with reductions in blood pressure and weight, and promotes a favourable lipid profile. In this review, we address the impact of dapagliflozin on cardiovascular risk factors and common microangiopathic complications such as kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate its potential beneficial effects on other less frequent complications of diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i in clinical practice is discussed. Our goal is to help translate this evidence into clinical practice.
Filiaciones:
Bellido V:
Endocrinology and Nutrition Department, Virgen del Rocío University Hospital, Sevilla, Spain
Martínez J:
Medical Department, AstraZeneca Spain, Madrid, Spain
Calvo F:
Endocrinology and Nutrition Department, "Lozano Blesa" Clinical Hospital, Zaragoza, Spain
Villarroel A:
Medical Department, AstraZeneca Spain, Madrid, Spain
Lecumberri E:
Endocrinology and Nutrition Department, Ramón y Cajal University Hospital, Madrid, Spain
Moreno J:
Medical Department, AstraZeneca Spain, Madrid, Spain
:
Endocrinology and Nutrition Department, Dr Peset University Hospital of Valencia, Valencia, Spain
Rodrigo S:
Medical Department, AstraZeneca Spain, Madrid, Spain
Izarra A:
Medical Department, AstraZeneca Spain, Madrid, Spain
Lecube A:
Research Group On Obesity, Diabetes and Metabolism (ODIM), Institute of Biomedical Research of Lleida (IRBLleida), Endocrinology and Nutrition Department, Arnau de Vilanova University Hospital, Lleida, University of Lleida, Avda. Rovira Roure 80, 25198, Lleida, Spain.
Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Carlos III Health Institute, Madrid, Spain.
gold, Green Published
|